Catherine M. Szyman - 19 Feb 2025 Form 4 Insider Report for Inari Medical, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 19 Feb 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Feb 2025, 20:20:54 UTC
Prior SEC filing: 14 Feb 2025
Next SEC filing: 13 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Shannon Trevino, attorney-in-fact for Catherine Szyman

Key filing fact

Catherine M. Szyman filed Form 4 for Inari Medical, Inc. on 19 Feb 2025.

Key facts

This page summarizes Catherine M. Szyman's Form 4 filing for Inari Medical, Inc..
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 Feb 2025, 20:20.

Change

Previous filing in this sequence was filed on 14 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NARI transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -22,429
Change %: -100%
Price
Shares after: 0
Date: 19 Feb 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NARI transaction Derivative

Stock Option

Disposed to Issuer

Transaction value
Shares: -49,719
Change %: -100%
Price
Shares after: 0
Date: 19 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 49,719
Exercise price: $5.73
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Catherine M. Szyman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.

Footnote F2

Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.

Footnote F3

At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.